Benperidol

Pharmacology

Pharmacodynamics

Benperidol is a strong dopamine receptor antagonist (D2 (Ki 0.027 nM) and D4 (Ki 0.066 nM)) with weaker serotonin receptor antagonism (5-HT2A (Ki 3.75 nM)). In high doses, it has antihistaminergic and alpha-adrenergic properties. It possesses minimal anticholinergic properties.

Although benperidol was developed relatively early in the history of antipsychotic drugs, it exhibits a uniquely high and selective affinity for the human dopamine D2 receptor when compared with all other human dopamine receptor subtypes. This is evident from its nanomolar binding affinities, which stand out even among both typical and atypical antipsychotics. Benperidol is also considered to possess one of the greatest selectivity ratios for dopamine receptors over 5-HT2A serotonin receptors, although this distinction is surpassed by certain neuroleptics such as amisulpride and sulpiride. Dopamine receptors play central roles not only in cognition, emotion, and motor control—key domains affected in schizophrenia—but also in various unconscious biological processes. The emphasis on D2 receptor blockade in antipsychotic drug design stems from its critical role in these functions and its dense expression in brain regions implicated in schizophrenia, such as the striatum and frontal cortex. Benperidol's preferential binding to the D2 receptor—over other dopamine receptor subtypes such as D3 and D4—is also unusually strong, with approximately a twofold greater selectivity. This distinguishes it from antipsychotics like haloperidol and perphenazine, which show more balanced D2/D3 binding ratios (e.g., 0.7–0.3 or 0.13), as well as from cariprazine, which demonstrates an even higher D3 affinity relative to D2 (D2–D3 ratio of 0.49–0.085).

Pharmacokinetics

Benperidol is absorbed well and undergoes extensive first pass metabolism. One percent of benperidol is excreted in urine. The half-life of benperidol is 8 hours.

Synthesis

4-(2-Keto-1-benzimidazolinyl)piperidine (1) is alkylated with 4-chloro-4'-Fluorobutyrophenone (2) to produce benperidol (3).

References

References

1. (1974-02-01). "Benperidol - a drug for sexual offenders?". BMJ Publishing Group Ltd.
2. British National Formulary (49th), British Medical Association 2005 p 183
3. (October 1963). "[Benperidol and promazine: a "double blind" comparative study in mental geriatrics]". Acta Neurologica et Psychiatrica Belgica.
4. (2001). "Neuroleptika: pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen; mit 136 Tabellen.". Wiss. Verlag-Ges..
5. (November 1975). "Endocrine changes in male sexual deviants after treatment with anti-androgens, oestrogens or tranquillizers". The Journal of Endocrinology.
6. "NCATS Inxight Drugs — BENPERIDOL".
7. (April 2005). "Benperidol for schizophrenia". The Cochrane Database of Systematic Reviews.
8. "PDSP K_i Database". University of North Carolina at Chapel Hill and the United States National Institute of Mental Health.
9. (December 2016). "Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future". Current Topics in Medicinal Chemistry.
10. (2009). "Amisulpride is a potent 5-HT7 antagonist: Relevance for antidepressant actions in vivo". Psychopharmacology.
11. (2016). "Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future". Current Topics in Medicinal Chemistry.
12. (2009). "The story of antipsychotics: Past and present". Indian Journal of Psychiatry.
13. (2020). "The role of dopamine D(3) receptors in the mechanism of action of cariprazine". CNS Spectrums.
14. (1998). "Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding". The Journal of Pharmacology and Experimental Therapeutics.
15. (2016). "Mechanism of action of cariprazine". CNS Spectrums.
16. "Benperidol". Thieme.
17. "1-(1-Aroylpropyl-4-piperidyl)-2-benzimidazolinones }} Chemical Abstracts 60, 10690c (1964), corresp. to {{cite patent".